Novo Nordisk to affirm superiority of CagriSema in obesity market
Eli Lilly recently received FDA approval for Zepbound, a GLP-1 weekly injectable drug to treat obesity.
Source: biopharma-reporter.com
Page 27 - Bio Developments News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Bio Developments. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Bio Developments Today - Breaking & Trending Today
FDA delays decision on Bristol-Myers Squibb, 2seventy bio cancer drug
The FDA has delayed its decision on whether to approve Bristol Myers Squibb and 2seventy bio’s CAR-T cell therapy, as it plans to seek further advice from experts.
Source: biopharma-reporter.com
Arrowhead Phamaceuticals' plozarsiran and zodasiran hold potential to treat dyslipidemia
At the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia, Arrowhead Pharmaceuticals unveiled the phase 2 clinical data for plozasiran (ARO-APOC3) and zodasiran (ARO-ANG3).
Source: biopharma-reporter.com
SynaptixBio awarded Innovate UK grant to expand search for rare disease therapies
Oxford-based SynaptixBio, whose aim is to find a treatment for TUBB4A-related leukodystrophies, has been awarded a £490,000 BioMedical Catalyst grant from Innovate UK to tackle less common variants of the disease.
Source: biopharma-reporter.com
Why Sirio is bringing its nutraceutical combinations to a pharma setting
At last month’s CPHI Barcelona, Sirio launched its new ready-to-market menopause and eye health softgels in a bid to collaborate with over the counter (OTC) brands and large pharmacy chains looking to advance to market faster.
Source: biopharma-reporter.com